Is GELS or GENB more undervalued in 2026?

CirclFi compares Gelteq Limited (GELS) and Generate Biomedicines, Inc. (GENB) using 13 institutional-grade valuation models. GELS has a Quality of Company score of 6.0/10 while GENB scores 1.8/10.

Which is a better buy — GELS or GENB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GELS and GENB valuations compare?

GELS at $0.49 and GENB at $13.12 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GELS vs GENB Valuation Comparison 2026 — Intrinsic Value Analysis

GELS

Pharmaceutical Preparations

Gelteq Limited

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.49

Last close

Models

10/13

Active

GENB

Pharmaceutical Preparations

Generate Biomedicines, Inc.

Quality

1.8

out of 10

Value Trap

—

Price

$13.12

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	GELS Fair Value	GELS Upside	GENB Fair Value	GENB Upside
Bayesian DCF	Intrinsic	$0.23	-53.7%	$3.57	-72.8%
Earnings Power Value	Intrinsic	$0.91	+37.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$0.82	+66.7%	$8.93	-31.9%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GELS vs GENB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GELS vs GENB — Which Stock Is More Undervalued?

GELS scores higher with a 6.0/10 quality rating vs GENB's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Gelteq Limited (GELS) and Generate Biomedicines, Inc. (GENB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GELS currently trades at $0.49 with a QOC of 6.0/10, while GENB trades at $13.12 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).